Hospital Volume Does Not Influence in-Hospital Mortality of Autologous Hematopoietic Cell Transplant Among Multiple Myeloma Patients in the United States

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 392-392
Author(s):  
Smith Giri ◽  
Prajwal Dhakal ◽  
Kathan Dilipbhai Mehta ◽  
Vijaya R. Bhatt

Abstract Introduction: Hospital volume and provider experience affects survival among patients with hematologic malignancies (Giri et al Blood 3359-60). Whether hospital volume affects outcomes of autologous hematopoietic cell transplant (autoSCT) among patients with multiple myeloma (MM) remains unclear. Methods: We utilized the Nationwide Inpatient Sample (NIS) database to identify all adults >18 years diagnosed with MM who underwent autoSCT in 2009-2011. NIS is the largest all-payer inpatient database in the US that captures about 20% of all US hospitalizations. Hospitals were divided into quartiles, based on the annual number of autoSCT performed, and classified into high volume (above 75th percentile) and low volume centers (below 25th percentile). In-hospital outcomes including inpatient mortality, infection, mechanical ventilation, and costs of hospitalization were compared between the two groups. All p-values were 2 sided, and the level of significance was chosen at 0.05. Statistical analysis was done using STATA 13.0 (StataCorp, College Station, TX). Results: A total of 2,750 autoSCTs were reported among patients with MM during the study period. The characteristics of study population included mean age of 58.7 ± 8.7 years, 56% males (n=1547) and 72% whites (n=1822). No significant difference existed in in-hospital mortality rate (0.86% vs. 1.59%; p=0.183) between high volume (≥178 autoSCTs per year) versus low volume centers (≤56 autoSCTs per year). The rate of fungal infection (5.32% vs. 4.94%; p=0.75), herpes simplex virus infection (1.58% vs. 1.59%; p=0.98), and the need for mechanical ventilation (1.87% vs. 1.27%) was similar between the high volume and low volume centers. Higher rates of stomatitis (57% vs. 46%; p<0.01), use of total parenteral nutrition (12.37% vs. 6.21%) and neutropenic fever (33.6% vs. 23.5%; p <0.01) were noted in high volume versus low volume centers. The cost of initial hospitalization was similar in the two groups (mean $ 161,085 vs. $ 154,161; p value 0.17). Conclusion: Our study demonstrates a low risk of inpatient mortality without center effect for autoSCT in MM in the recent years. The risks of fungal and herpes simplex virus infection were also similar between high volume and low volume centers. Higher rates of stomatitis, use of total parenteral nutrition and neutropenic fever were noted in high volume versus low volume centers. The reasons for these differences are not clear from our study but may relate to possible differences in patient characteristics or conditioning chemotherapy. Disclosures No relevant conflicts of interest to declare.

2016 ◽  
Vol 82 (5) ◽  
pp. 407-411 ◽  
Author(s):  
Thomas W. Wood ◽  
Sharona B. Ross ◽  
Ty A. Bowman ◽  
Amanda Smart ◽  
Carrie E. Ryan ◽  
...  

Since the Leapfrog Group established hospital volume criteria for pancreaticoduodenectomy (PD), the importance of surgeon volume versus hospital volume in obtaining superior outcomes has been debated. This study was undertaken to determine whether low-volume surgeons attain the same outcomes after PD as high-volume surgeons at high-volume hospitals. PDs undertaken from 2010 to 2012 were obtained from the Florida Agency for Health Care Administration. High-volume hospitals were identified. Surgeon volumes within were determined; postoperative length of stay (LOS), in-hospital mortality, discharge status, and hospital charges were examined relative to surgeon volume. Six high-volume hospitals were identified. Each hospital had at least one surgeon undertaking ≥ 12 PDs per year and at least one surgeon undertaking < 12 PDs per year. Within these six hospitals, there were 10 “high-volume” surgeons undertaking 714 PDs over the three-year period (average of 24 PDs per surgeon per year), and 33 “low-volume” surgeons undertaking 225 PDs over the three-year period (average of two PDs per surgeon per year). For all surgeons, the frequency with which surgeons undertook PD did not predict LOS, in-hospital mortality, discharge status, or hospital charges. At the six high-volume hospitals examined from 2010 to 2012, low-volume surgeons undertaking PD did not have different patient outcomes from their high-volume counterparts with respect to patient LOS, in-hospital mortality, patient discharge status, or hospital charges. Although the discussion of volume for complex operations has shifted toward surgeon volume, hospital volume must remain part of the discussion as there seems to be a hospital “field effect.”


2021 ◽  
Vol 27 (3) ◽  
pp. S47
Author(s):  
Pashna N. Munshi ◽  
David H. Vesole ◽  
Andrew St. Martin ◽  
Omar Davila ◽  
Parameswaran Hari ◽  
...  

2005 ◽  
Vol 35 (12) ◽  
pp. 1133-1140 ◽  
Author(s):  
M Arora ◽  
P B McGlave ◽  
L J Burns ◽  
J S Miller ◽  
J N Barke ◽  
...  

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1124-1124
Author(s):  
Scott A Schwantes ◽  
Marie E Steiner ◽  
Qing Cao ◽  
K. Scott Baker ◽  
Sameer Gupta

Abstract Background: Pediatric hematopoietic cell transplant (HCT) patients requiring mechanical ventilation have historically had poor outcomes with high mortality rates. However, recent studies have shown an improvement in the overall outcomes for patients requiring mechanical ventilation (18% improved to 59% survival, Kache S et al 2006). One subset that has persistently had poor outcomes is the patient group requiring high frequency oscillatory ventilation (HFOV) with published mortality rates of 89–100% (Kache S et al 2006, Hagen S et al 2003). However, Hagen et al also noted that patients placed on HFOV within 6 hours of intubation had better survival than those managed with conventional ventilation for longer intervals before conversion to HFOV. We report our experience at a large pediatric HCT center with mechanical ventilation and, more specifically, the largest single center experience with HFOV. Methods: Records of all pediatric HCT patients from 1/2000 through 7/2007 (n=522) who required mechanical ventilation (n=139) and/or HFOV (n=36) were retrospectively reviewed to identify conditions of the patient at the time of initial intubation, as well as co-morbidities during the period of intubation. Results: At one year after HCT, 69.7% (364/522) of all patients were alive. For nonventilated patients, 79.6% (305/383) were alive at one year compared to 42.4% (59/139) of all patients over the entire interval who required mechanical ventilation. For patients who required mechanical ventilation but not HFOV, 47.6% (49/103) survived compared to 27.8% (10/36) of patients who required HFOV. With respect to patients requiring HFOV, renal replacement therapy at any point was associated with a significant (p=0.04) risk for in-hospital mortality. No other significant factors associated with increased mortality were identified in patients requiring HFOV, including age, gender, initial diagnosis, stem cell source, etc. Specifically, no increase in mortality was seen with umbilical cord blood transplants in contrast to the experience of Hagen et al. When comparing 1 year survival of patients who were transplanted in the earliest interval 2000–2001 versus those transplanted in current years 2005–2007, we did note a significant increase in survival for all HCT patients (62.5% increased to 77.7%, p = 0.01) and for those HCT patients that required mechanical ventilation (38.3% increased to 58.5%, p=0.04). There was a trend toward improvement in survival over time for those patients who required HFOV (22.2% 2000–2001 to 33.3% 2005–2007), but the difference was not significant due to the small number of patients. 50% of all patients converted to HFOV within one day of initiating mechanical ventilation survived; of the HFOV survivors, 67% were converted to HFOV within one day of intubation and all but 2 survivors were converted within 2 days of intubation. Conclusions: Despite the historically poor outcomes of HCT recipients who require HFOV, our data suggests HCT patients with respiratory failure managed with HFOV can have reasonable expectations for survival, including umbilical cord blood transplant patients. The need for renal replacement therapy in patients requiring HFOV significantly increases the risk of mortality. We identified no additional risk factors contributing to mortality comparing other demographic data or other co-morbidities. Institution of HFOV early in HCT patients’ ventilator course may improve survival. Further definition of optimal HFOV management strategies remains to be investigated as well as the pathophysiology underlying the apparent enhanced survival with earlier HFOV use.


2017 ◽  
Vol 17 (1) ◽  
pp. e112
Author(s):  
Chrysanthi Vadikoliou ◽  
Zoi Bousiou ◽  
Maria Kaliou ◽  
Anastasia Athanasiadou ◽  
Ioanna Sakellari ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document